ADMA Biologics ADMA 深 沪
等待开盘 08-10 09:30:00 美东时间
9.90
-0.160
-1.59%
华盛通- 最 高10.35
- 今 开9.97
- 成交量 315.09万股
- 最 低 8.66
- 昨 收 10.06
- 总市值 194.04万
- 52周最高 20.458
- 市盈率 静 --
- 换手率 1607.58%
- 52周最低 7.2101
- 委 比 90.87%
- 总股本 0.00亿
- 历史最高 25.67
- 量 比 1.12
- 振 幅 16.80%
- 历史最低 1.01
- 每 手 1
- 风险率 3.91%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Cantor Fitzgerald Downgrades ADMA Biologics to Neutral
Cantor Fitzgerald analyst Kristen Kluska downgrades ADMA Biologics (NASDAQ:ADMA) from Overweight to Neutral.
03-26 18:00
Short Seller Report Alleges ADMA Biologics Financial Misrepresentation
ADMA Biologics shares drop after Culper Research short report alleges financial misreporting; company pushes back.
03-26 01:22
ADMA Responds To Short-Seller Report, Reviewing Assertions For Accuracy
ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), a U.S. based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, today addressed a
03-25 18:35
Preview: ADMA Biologics's Earnings
ADMA Biologics (NASDAQ:ADMA) is gearing up to announce its quarterly earnings o...
02-25 00:02
What's Driving the Market Sentiment Around ADMA Biologics?
ADMA Biologics's (NYSE:ADMA) short percent of float has risen 4.18% since its l...
2025-03-11 23:45
In-Depth Examination Of 4 Analyst Recommendations For ADMA Biologics
In the latest quarter, 4 analysts provided ratings for ADMA Biologics (NASDAQ:A...
2024-09-21 05:01
Cantor Fitzgerald Reiterates Overweight on ADMA Biologics, Maintains $20 Price Target
Cantor Fitzgerald analyst Kristen Kluska reiterates ADMA Biologics (NASDAQ:ADMA) with a Overweight and maintains $20 price target.
2024-09-20 23:10
What's Going On With ADMA Biologics Stock Monday?
ADMA Biologics shares are moving higher after it was announced that the company will join the S&P SmallCap 600.
2024-09-10 01:42
Terns Pharmaceuticals, Boeing, Tesla And Other Big Stocks Moving Higher On Monday
U.S. stocks were higher, with the Dow Jones index gaining around 400 points on ...
2024-09-09 22:13
'This Is A Very Speculative Situation,' Jim Cramer On ADMA Biologics
On CNBC's “Mad Money Lightning Round,” Jim Cramer said, “This is a very speculative situation,” when asked about ADMA Biologics, Inc. (NASDAQ:ADMA). “Any time there's immunity-compromised patients, there's some big money down the road,” he added. On Aug. 8, ADMA Biologics reported better-than-expect...
2024-08-30 21:09
